$SYN News Article - Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol https://marketwirenews.com/news-releases/synt...70584.html
(0)
(0)
Theriva Biologics, Inc. (TOVX) Stock Research Links